[1]金志鑫,许 明.雷贝拉唑联合蓝芩口服液治疗慢性咽炎的效果及对患者临床症状、炎性因子和免疫功能的影响[J].医学信息,2023,36(24):91-94.[doi:10.3969/j.issn.1006-1959.2023.24.019]
　JIN Zhi-xin,XU Ming.Effect of Rabeprazole Combined with Lanqin Oral Solution in the Treatment of Chronic Pharyngitis and its Influence on Clinical Symptoms, Inflammatory Factors and Immune Function[J].Journal of Medical Information,2023,36(24):91-94.[doi:10.3969/j.issn.1006-1959.2023.24.019]
点击复制

雷贝拉唑联合蓝芩口服液治疗慢性咽炎的效果及对患者临床症状、炎性因子和免疫功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年24期
页码:
91-94
栏目:
论著
出版日期:
2023-12-15

文章信息/Info

Title:
Effect of Rabeprazole Combined with Lanqin Oral Solution in the Treatment of Chronic Pharyngitis and its Influence on Clinical Symptoms, Inflammatory Factors and Immune Function
文章编号:
1006-1959（2023）24-0091-04
作者:
金志鑫; 许 明
（天津市第三中心医院分院耳鼻喉科，天津 300250）
Author(s):
JIN Zhi-xin; XU Ming
(Department of Otorhinolaryngology,Branch of Tianjin Third Central Hospital,Tianjin 300250,China)
关键词:
慢性咽炎; 雷贝拉唑; 蓝芩口服液; 炎性因子; 免疫功能
Keywords:
Chronic pharyngitis; Rabeprazole; Lanqin oral solution; Inflammatory factors; Immune function
分类号:
R571
DOI:
10.3969/j.issn.1006-1959.2023.24.019
文献标志码:
A
摘要:
目的 研究雷贝拉唑联合蓝芩口服液治疗慢性咽炎的效果及对患者临床症状、炎性因子及免疫功能的影响。方法 选取2021年6月-2022年6月天津市第三中心医院分院耳鼻喉科就诊的74例慢性咽炎患者，经随机数字表法分为对照组（37例）与观察组（37例）。两组均给予布地奈德雾化吸入治疗，在此基础上，对照组加用蓝芩口服液治疗，观察组则应用雷贝拉唑联合蓝芩口服液治疗，比较两组治疗效果、临床症状、症状缓解时间、炎性因子[肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）]、免疫功能[外周血T淋巴细胞亚群（CD4+、CD8+、CD4+/CD8+）]。结果 观察组治疗总有效率为94.59%，高于对照组的78.38%（P＜0.05）；观察组症状评分（咽部干痒、声音嘶哑、异物感、咽部堵塞）低于对照组（P＜0.05）；观察组症状缓解时间（咽部干痒、声音嘶哑、异物感、咽部堵塞）短于对照组（P＜0.05）；观察组TNF-α、IL-6水平低于对照组（P＜0.05）；观察组CD4+、CD4+/CD8+高于对照组（P＜0.05）。结论 雷贝拉唑联合蓝芩口服液治疗慢性咽炎疗效肯定，可改善患者的临床症状，加速其症状缓解，同时下调体内炎性因子，促进机体免疫功能提升。
Abstract:
Objective To study the effect of rabeprazole combined with Lanqin oral solution in the treatment of chronic pharyngitis and its effect on clinical symptoms, inflammatory factors and immune function.Methods A total of 74 patients with chronic pharyngitis who were admitted to the Department of Otorhinolaryngology, Branch of Tianjin Third Central Hospital from June 2021 to June 2022 were selected and divided into control group (37 patients) and observation group (37 patients) by random number table method. Both groups were treated with budesonide atomization inhalation. On this basis, the control group was treated with Lanqin oral solution, while the observation group was treated with rabeprazole combined with Lanqin oral solution. The therapeutic effect, clinical symptoms, symptom relief time, inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)], immune function [peripheral blood T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+)] were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.59%, which was higher than 78.38% in the control group (P<0.05). The symptom scores (throat itching, hoarseness, foreign body sensation, pharyngeal obstruction) in the observation group were lower than those in the control group (P<0.05). The symptom relief time (throat itching, hoarseness, foreign body sensation, pharyngeal obstruction) in the observation group was shorter than that in the control group (P<0.05). The levels of TNF-α and IL-6 in the observation group were lower than those in the control group (P<0.05). CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05).Conclusion Rabeprazole combined with Lanqin oral solution is effective in the treatment of chronic pharyngitis, which can improve the clinical symptoms of patients, accelerate the relief of symptoms, down-regulate inflammatory factors in the body, and promote the improvement of immune function.

参考文献/References:

[1]Pukhlik SM,Suvorkina AA.Chronic pharyngitis, a condition of a problem. An algorithm for the diagnosis of chronic pharyngitis of an allergic nature[J].Otorhinolaryngology,2020,4(2):74-78.[2]汪姬婵,陈学明,王国芳.黄氏响声丸联合布地奈德治疗慢性咽炎的临床研究[J].现代药物与临床,2019,34(10):2990-2993.[3]彭里.金嗓利咽胶囊联合蓝芩口服液治疗慢性咽喉炎的临床疗效[J].现代诊断与治疗,2022,33(20):3011-3014.[4]付晓梅,王青青,张宏,等.蓝芩口服液联合头孢克肟治疗小儿急性咽炎的临床研究[J].现代药物与临床,2021,36(1):161-164.[5]高宝玉,李月梅,马琳娟,等.门诊慢性咽炎患者咽喉反流性疾病的流行病学调查[J].中国中西医结合耳鼻咽喉科杂志,2019,27(6):457-458,466.[6]Xu H,O’Gorman MT,Nepal S,et al.Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants[J].Clin Pharmacol Drug Dev,2021,10(11):1395-1404.[7]郭小陪,郭思军,王蒙.雷贝拉唑联合伊托必利治疗反流性食管炎临床疗效及安全性观察[J].贵州医药,2022,46(6):872-873.[8]Gostry AV,Simonova AV,Mikhailova NA,et al.Chronic pharyngitis: etiology, pathogenesis, treatment.new approaches to the estimation of etiopatogenesis[J].The Russian Archives of Internal Medicine,2019,9(1):32-43.[9]李宏,尹李虎.蓝芩口服液联合阿莫西林克拉维酸钾分散片治疗儿童急性扁桃体炎的效果及对细胞免疫因子的调控[J].药物评价研究,2021,44(1):147-151.[10]Tanabe T,Oridate N.Chronic pharyngitis and laryngitis caused by gastroesophageal reflux[J].Nihon Rinsho,2016,74(8):1367-1371.[11]王光铭,黄玉珍,刘万里.通降合剂联合雷贝拉唑肠溶胶囊治疗反流性食管炎[J].中国临床研究,2020,33(4):531-535.[12]陈代波,麻宁,唐春霞,等.蓝芩口服液联合持续气道无创正压通气法治疗以慢性咽喉炎为主诉的OSA患者临床效果分析[J].湖北中医药大学学报,2021,23(3):69-71.[13]练万里,庄家用,徐春辉.蓝芩口服液治疗小儿疱疹性咽峡炎效果及对血清炎症因子水平的影响[J].儿科药学杂志,2020,26(1):30-32.[14]姚卫格,舒继红,尤小丽,等.康复新液联合雷贝拉唑治疗咽喉反流40例疗效分析[J].安徽医药,2022,26(6):1259-1263.[15]王少鑫,崔立红,弓三东,等.雷贝拉唑联用黛力新治疗难治性胃食管反流病的临床观察[J].现代医学,2020,48(3):348-352.[16]李芳芳,黄巨霞.雷贝拉唑联合莫沙必利对反流性食管炎患者幽门螺杆菌感染及炎症因子水平影响研究[J].陕西医学杂志,2019,48(10):1378-1380,1389.[17]张玲玲.雷贝拉唑钠肠溶片应用分析及合理性评价[J].河北医学,2018,24(6):1021-1025.[18]杨凌玲,谭莉.黛力新联合多潘立酮、雷贝拉唑治疗老年难治性反流性食管炎的临床疗效研究[J].广西医科大学学报,2018,35(9):1245-1249.[19]李常军.雷贝拉唑联合莫沙必利治疗胃食管反流的临床效果及对患者食管运动功能的影响[J].检验医学与临床,2019,16(8):1118-1120.[20]陈玲,赵文静,孙艳,等.蓝芩口服液配合干扰素α1b注射液对疱疹性咽峡炎患儿炎性因子及体液免疫水平的影响[J].海南医学,2021,32(23):3082-3085.[21]岑宗泽,周育毅,王小洁.中西医结合治疗慢性咽炎的临床疗效分析[J].广西医科大学学报,2019,36(4):625-627.

相似文献/References:

[1]王 剑.加减半夏厚朴汤联合葛根芩连汤治疗慢性咽喉炎的疗效观察[J].医学信息,2018,31(04):139.[doi:10.3969/j.issn.1006-1959.2018.04.050]
　WANG Jian.Observation on Curative Effect of Banxia Houpu Decoction Combined with Gegen Qinlian Decoction in Treating Chronic Pharyngitis[J].Journal of Medical Information,2018,31(24):139.[doi:10.3969/j.issn.1006-1959.2018.04.050]
[2]赵庚雷,张 凡,彭顺林.彭顺林教授采用利咽合剂联合穴位贴敷 治疗慢性咽炎病案1例[J].医学信息,2018,31(05):190.[doi:10.3969/j.issn.1006-1959.2018.05.072]
[3]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Journal of Medical Information,2018,31(24):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
[4]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Journal of Medical Information,2018,31(24):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[5]魏 巍.蓝芩口服液治疗慢性咽炎的临床效果观察[J].医学信息,2019,32(02):164.[doi:10.3969/j.issn.1006-1959.2019.02.050]
　WEI Wei.Clinical Observation of Lanqi Oral Liquid in Treating Chronic Pharyngitis[J].Journal of Medical Information,2019,32(24):164.[doi:10.3969/j.issn.1006-1959.2019.02.050]
[6]韩付金.雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片用于难治性良性胃溃疡的疗效[J].医学信息,2020,33(20):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
　HAN Fu-jin.Efficacy of Rabeprazole Enteric-coated Capsules Combined with Hydrotalcite Chewable Tablets for Refractory Benign Gastric Ulcer[J].Journal of Medical Information,2020,33(24):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
[7]张运林.铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性[J].医学信息,2020,33(24):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]
　ZHANG Yun-lin.The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer[J].Journal of Medical Information,2020,33(24):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]
[8]褚春沐.雷贝拉唑治疗进展性缺血性脑卒中的价值[J].医学信息,2022,35(14):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
　CHU Chun-mu.Value of Rabeprazole in Treatment of Progressive Ischemic Stroke[J].Journal of Medical Information,2022,35(24):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]

更新日期/Last Update: 1900-01-01